A personalized medicine diagnostics company assessing the activity of mutations and combination of mutations and their response to targeted drugs
Location: United States, Pennsylvania, Philadelphia
Total raised: $113M
Investors 3
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
| - | HBM Partne... | hbmpartner... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.05.2025 | Series D | $38M | - |
| 25.08.2023 | Series D | $75M | - |
Mentions in press and media 8
| Date | Title | Description |
| 28.05.2025 | FORE Biotherapeutics: A New Dawn in Cancer Treatment with $38 Million Series D-2 Financing | In the ever-evolving landscape of cancer treatment, a new player is making waves. FORE Biotherapeutics, based in Philadelphia, has secured $38 million in Series D-2 financing. This funding marks a significant step forward in the company's m... |
| 23.05.2025 | FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of Plixorafenib | FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare... |
| 23.05.2025 | Fore Biotherapeutics Raises $38M in Series D-2 Financing | Fore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $38M ion Series D-2 financing. Backers included R One, Medicxi, OrbiM... |
| 25.08.2023 | Fore Biotherapeutics Raises $75M in Series D Financing | Fore Biotherapeutics, a Philadelphia, PA-based precision oncology company, raised $75M in Series D funding. The round was led by SR One and Medicxi, with participation from existing investors OrbiMed, HBM Healthcare Investments, Novartis Ve... |
| 23.08.2023 | FORE Biotherapeutics raised a $75M Series D and announced an interim CEO | Update: Details about funding and employee count from a FORE spokesperson have been added. (8/23/23, 4:15 p.m.) University City-based FORE Biotherapeutics raised $75 million in a Series D round, the biotech company announced today. The roun... |
| 19.05.2021 | Fore Biotherapeutics Strengthens Leadership Team with Executive and Board Appointments | Company appoints biotech industry experts Stacie Peacock Shepherd, M.D., Ph.D., as Chief Medical Officer and Nora Brennan as Chief Financial Officer |
| 24.02.2021 | NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and D... | Company launch and rebrand in the US reflects expert leadership in precision oncology and a new business model optimized for speed to market by hyper-targeting patient populations with unaddressed tumor mutations to match them with validate... |
| - | Fore Biotherapeutics | “Fore Biotherapeutics” |